Abstracts

VORICONAZOLE OR AMPHOTERICIN B DEOXYCHOLATE: WHICH IS THE PREFERRED INDUCTION THERAPY

Even in the era of widespread ART, HIV-associated talaromycosis is still common in endemic areas globally. Current guidelines recommend liposomal amphotericin B as the preferred induction therapy, but liposomal amphotericin B is not available in certain settings. Induction therapy with amphotericin B deoxycholate or voriconazole has been shown to be effective treatments for talaromycosis. However,…

CLUSTER RCT OF A MID-LEVEL MANAGER INTERVENTION TO PROMOTE IPT UPTAKE IN UGANDA

Despite longstanding guidelines endorsing isoniazid preventive therapy (IPT) for persons with HIV, uptake is low across sub-Saharan Africa. Mid-level health managers oversee IPT programs nationally; interventions aimed at this group have not been tested. We conducted a cluster randomized trial in Uganda among district-level health managers from 2017-2021. The unit of randomization was groups of…

RANDOMIZED CONTROLLED TRIAL OF ADJUNCTIVE ROSUVASTATIN FOR TUBERCULOSIS TREATMENT

In vitro and animal model data suggest statins may have benefit as adjunctive host-directed therapy for tuberculosis. Rosuvastatin has minimal interaction with rifampicin and is available in generic formulation. We hypothesised that rosuvastatin, at standard treatment doses used for lipid reduction, might accelerate sputum culture conversion. We randomised patients with rifampicin-susceptible TB (smear ?1 positive…